[Preliminary evaluation of the pharmacokinetics and toxicity of esorubicin].
作者信息
Piazza E, Negretto E, Vago G, Pacciarini M A, Tamassia V
出版信息
G Ital Chemioter. 1985 Jan-Apr;32(1):21-4.
PMID:3830780
Abstract
摘要
相似文献
1
[Preliminary evaluation of the pharmacokinetics and toxicity of esorubicin].[表柔比星的药代动力学及毒性初步评估]
G Ital Chemioter. 1985 Jan-Apr;32(1):21-4.
2
Phase II trial of esorubicin in patients with advanced colorectal carcinoma.表柔比星用于晚期结直肠癌患者的II期试验。
Cancer Treat Rep. 1986 Oct;70(10):1241-2.
3
Pharmacokinetics of liposomal doxorubicin (TLC-D99; Myocet) in patients with solid tumors: an open-label, single-dose study.脂质体阿霉素（TLC-D99；Myocet）在实体瘤患者中的药代动力学：一项开放标签、单剂量研究。
Cancer Chemother Pharmacol. 2004 Dec;54(6):514-24. doi: 10.1007/s00280-004-0825-y. Epub 2004 Aug 21.
4
Phase II trial of esorubicin (4'deoxydoxorubicin, DxDx) in patients with small cell lung cancer.
Invest New Drugs. 1991 May;9(2):187-90. doi: 10.1007/BF00175087.
5
A phase II evaluation of esorubicin in ovarian cancer. A Southwest Oncology Group study.表柔比星治疗卵巢癌的II期评估。西南肿瘤协作组的一项研究。
Am J Clin Oncol. 1992 Apr;15(2):146-9. doi: 10.1097/00000421-199204000-00010.
6
Pharmacokinetics and metabolism of pirarubicin in humans: correlation with pharmacodynamics.吡柔比星在人体内的药代动力学与代谢：与药效学的相关性。
Cancer Chemother Pharmacol. 1995;36(3):239-43. doi: 10.1007/BF00685853.
7
Phase II study of weekly low-dose 4'-epi-doxorubicin in advanced postmenopausal breast cancer.每周低剂量4'-表阿霉素治疗晚期绝经后乳腺癌的II期研究。
Cancer Treat Rep. 1984 Apr;68(4):675-7.
8
Phase II trial of esorubicin (4' deoxydoxorubicin) in cancers of the breast, colon, kidney, lung and melanoma.表柔比星（4'-脱氧多柔比星）用于乳腺癌、结肠癌、肾癌、肺癌及黑色素瘤的II期试验。
Invest New Drugs. 1986;4(3):269-74. doi: 10.1007/BF00179595.
9
Cardiotoxicity associated with 4'-deoxydoxorubicin.
Cancer Treat Rep. 1986 Mar;70(3):433.
10
[Pharmacokinetics and acute signs of cardiac toxicity during doxorubicin therapy].[多柔比星治疗期间的药代动力学及心脏毒性急性体征]
Wien Klin Wochenschr. 1983 Jan 21;95(2):52-5.
Zotero 插件